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Introduction
Inflammation and glucocorticoid therapy are major factors
in the growth retardation seen in children with severe
forms of juvenile idiopathic arthritis (JIA).
Objectives
The objective of the this study was to evaluate effects of
antirheumatic treatment with recombinant humanised
monoclonal antibody that acts as IL-6R antagonist
(tocilizumab ) on longitudinal growth.
Methods
Nineteen patients with systemic JIA was included into
the study (8 boys and 11 girls). The mean age at first
visit was 6.8 ± 2.4 years, and disease duration 4 (2,2;6)
years. All patients had stage 1 of sexual development by
Tanner scale and before therapy with tocilizumab had
standard antirheumatic therapy. Anthropometric para-
meters were estimated one year before tocilizumab
treatment, at the day of first infusion and in one year
after tocilizumab treatment was started. SDS for height
and height velocity calculated against the growth curves
for European population (Auxology, Pfizer, Version 1.0).
Tocilizumab was administered intravenously once
every 2 weeks at a dose of 8-12 mg/kg of body weight.
In all patients who received corticosteroids before tocili-
zumab treatment dose of prednisolone was reduced
from 0.5 (0.4; 0.6) to 0.1 (0.02; 0.2), but not in one case
it was completely abolished. Treatment efficacy was
assessed according to criteria ACR pedi scale.
Results
Clinical response to the treatment was obtained in all
patients included in this study. The ACR Pedi 50, 70 and
90 improvement were achieved by 3, 3, and 1 patients at
Week 52, Inactive disease was achieved by 11 patients at
week 52. The mean height SDS one year before treatment
was -2.38 ±1.43 and -2.64±1.94 by the day of 1st
tocilizumab infusion (p < 0.001). Height velocity SDS was
-4.24 ±1.18 and -4.55 ±1.49 respectively (p < 0.001). After
one year of treatment the mean height SDS was
-2.27 ±1.85 and height velocity SDS 2.51 ±1.98 (p < 0.001).
Conclusion
An intensified antirheumatic treatment with tocilizumab
has a beneficial effect on growth in children with JIA. This
effect might be related to the inhibitory effect of proin-
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